OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.
Business Model:
Revenue: $0
Employees: 11-50
Address: 300 Fifth Avenue
City: Waltham
State: MA
Zip: 02451
Country: US
OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform. OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumor microenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes. The company was founded in 2018 and was formerly known as Oncologie.
Contact Phone:
+17819077810
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2019 | Series B | 4 | $80M |
Korea Investment Partners Nan Fung Life Sciences Panacea Venture Pivotal bioVenture Partners China Korea Investment Partners Nan Fung Life Sciences Panacea Venture Pivotal bioVenture Partners China |
6/2018 | Seed Round | 4 | $16.5M |
Pivotal bioVenture Partners China CMB International Capital Corporation Nan Fung Life Sciences Volcanics Venture Pivotal bioVenture Partners China Pivotal bioVenture Partners China CMB International Capital Corporation Nan Fung Life Sciences Volcanics Venture Pivotal bioVenture Partners China |
3/2022 | Venture Round | $30M | 2/2022 | Equity | $30M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|